Kymera's KT-474 is the first oral degrader to demonstrate activity in clinical trials outside cancer and Sanofi recently started a Ph. II trial with the molecule in AD, restoring life to IRAK4 as an immunology target. This article highlights several reasons why Kymera’s KT-474 program is scientifically notable, including how it differentiates from small molecule inhibitors, potential competitiveness with biologics, the first reported cryo-EM ternary complex of a heterobifunctional degrader, and why this 2023 Molecule of the Year Nominee will likely be considered a “landmark in drug discovery” for some time.
12 minute read
Mar. 30, 2024
KT-474: The First Clinically Active Heterobifunctional Degrader Outside Oncology
KT-474
oral IRAK4 degrader Ph. II in AD and HS from SBDD of ligands for CRBN, IRAK4, and linker Nature Medicine, Nov. 2023 Kymera Therapeutics, Watertown, MA